<DOC>
	<DOCNO>NCT00600886</DOCNO>
	<brief_summary>The patient receive either Pasireotide LAR Octreotide LAR one year treatment . The objective study compare proportion patient reduction mean GH level &lt; 2.5 Âµg/L normalization IGF-1 within normal limit ( age sex relate ) two treatment group ( pasireotide LAR octreotide LAR ) 12 month . Following one year treatment patient may proceed study extension . Patients respond treatment randomize ( base month 12 assessment result ) switch treatment arm month 13 .</brief_summary>
	<brief_title>Safety Efficacy Pasireotide Long Acting Release ( LAR ) vs. Octreotide LAR Patients With Active Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Inclusion criterion : Patients active acromegaly ( base elevate GH IGF1 level ) Patients undergone one pituitary surgery , treat medically , denovo patient present visible pituitary adenoma MRI refuse pituitary surgery pituitary surgery contraindicate Patients write informed consent participate study obtain prior study related activity Exclusion criterion : Patients treat octreotide , lanreotide , dopamine agonist GH antagonists exception single dose shortacting octrotide shortacting dopamine agonist . In case single dose shortacting octrotide , dose use predict response octretide treatment . The single dose shortacting octreotide shortacting dopamine agonist administer 3 day prior randomization Patients compression optic chiasm cause visual field defect Patients receive pituitary irradiation within last ten year prior visit 1 Poorly control diabetic patient Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Acromegaly ,</keyword>
	<keyword>adult ,</keyword>
	<keyword>growth hormone ,</keyword>
	<keyword>insulin-like growth factor I ,</keyword>
	<keyword>somatostatin analogue</keyword>
</DOC>